practice opt in out

Please select one of the above
Please enter your first name
Please enter your last name
Please select an option
Please enter your practice name
Please enter your email address
Please enter your address
Please enter your phone number
Please enter your NPI number
*Required fields.
Please check this box

Our practice finder is intended to assist eye care professionals in finding practices in their area that have experience with SYFOVRE or treating geographic atrophy (GA).

By submitting, you give us permission to add or remove your practice information to/from the practice finder, and to contact you by email if we require further information.

Once you’ve submitted your request, our team will review your information and process your request. We may have to contact you for further information.†

  • By selecting "Sign me up to receive updates from Apellis," I authorize Apellis Pharmaceuticals, Inc, its affiliates and their representatives, agents, contractors and companies working with Apellis (collectively, “Apellis”), to contact me by mail, email, telephone, and text messages for marketing purposes or to otherwise provide me with information about Apellis products, services, and programs or other topics of interest; conduct market research; or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by Apellis to help develop new products, services, and programs. I understand that I may revoke this authorization and choose not to receive information from Apellis by clicking the “unsubscribe” link provided in emails I receive from Apellis. I have read and understand the Privacy Policy.

Frequently Asked Questions

  • Why is early intervention, such as early diagnosis and ongoing monitoring, critical in GA?

    Vision lost to GA progression can never be fully recovered and can harm multiple aspects of your patients' lives.1,2

  • How rapidly can GA vision loss progress?

    GA vision loss progresses faster than you may think. In fact, ~1 in 5 patients with GA become legally blind in their better–seeing eye within 1 year.3

    • Based on a retrospective analysis of clinical data recorded in the IRIS® Registry of electronic health records from 69,441 patients diagnosed with GA in 1 eye and GA or neovascular age-related macular degeneration (nAMD) in the other eye (mean baseline visual acuity was 63 letters [bilateral GA], 56 letters [unilateral GA]) between January 1, 2016 and December 31, 2017. Patients diagnosed with nAMD <3 years prior to GA in the study eye were excluded. N-values and percentages were calculated from subfoveal and nonsubfoveal patient subset data.3

  • What are the most common early warning signs of GA?

    Screening for GA often starts by knowing the key risk factors for the development of GA, including family history, history of smoking, diet, obesity, certain dyslipidemias, cardiovascular disease, and clinical findings from imaging such as GA in fellow eye or increased drusen volume. Patients with GA may experience straight lines that appear distorted, dull or washed-out colors, blurred vision, difficulty seeing in low light, reduced central vision, or missing spots in vision.1,4-7

  • How many SYFOVRE® (pegcetacoplan injection) clinical trials have been conducted?

    SYFOVRE has an unmatched amount of clinical evidence in GA, with the largest and longest clinical data set of any approved GA treatment. The clinical trials of SYFOVRE include two 2-year double-masked trials (OAKS and DERBY) and the 3-year open-label GALE extension trial.8-11

    Learn more

  • How many patients were included in the SYFOVRE (pegcetacoplan injection) clinical trials?

    SYFOVRE was studied in clinical trials over 5 years in >1200 patients with GA secondary to AMD with either subfoveal (SF) or nonsubfoveal (NSF) lesions.8,9

    Learn more

  • What treatment effects were assessed in the 5-year GALE open-label extension study?

    GALE measured retinal tissue preservation and slowing of GA lesion growth over 5 years vs projected sham.12

    Learn more

  • In which patient population was SYFOVRE (pegcetacoplan injection) studied?

    Patients with GA secondary to AMD with SF or NSF lesions in the study eye or choroidal neovascularization (CNV) in the fellow eye were enrolled in all Phase 3 clinical trials8,9,11,13

    • SF lesions typically grow at a slower rate than NSF lesions
    • Patients with GA secondary to a condition other than age-related macular degeneration and history or presence of CNV in the study eye were excluded
    Learn more

  • Does SYFOVRE (pegcetacoplan injection) have tissue preservation data?

    Yes, tissue preservation was evaluated over 5 years in GALE.12,14

    Learn more

  • What discontinuation rates were seen in the clinical trials of SYFOVRE (pegcetacoplan injection)?

    In clinical trials of SYFOVRE, discontinuation rates through 2 years (SYFOVRE monthly vs SYFOVRE every other month vs sham pooled, respectively) were 31% vs 21% vs 25% in OAKS and 29% vs 22% vs 21% in DERBY.8

    Discontinuation rates (SYFOVRE monthly vs SYFOVRE every other month vs pooled crossover from sham) were 29% vs 33% vs 37% over 5 years in GALE.12

    Learn more

  • What are the most common SYFOVRE® (pegcetacoplan injection) adverse reactions?

    The most common adverse reactions (≥5%) reported in patients receiving SYFOVRE were ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, and conjunctival hemorrhage.8*

    The following reported items were combined: ocular discomfort (included: eye pain, eye irritation, foreign body sensation in eyes, ocular discomfort, abnormal sensation in eye), nAMD (included: exudative age-related macular degeneration, choroidal neovascularization).8
    Learn more

  • What is the reported rate of retinal vasculitis with SYFOVRE (pegcetacoplan injection) in the real world?

    ~900,000 injections in clinical trials and real-world settings have been administered to ~130,000 patients. Retinal vasculitis has been confirmed in 30 patients. Over 3 years, 12 patients experienced severe vision loss (7 patients in 2023, 5 patients in 2024, 0 patients in 2025).*† Retinal vasculitis is primarily a first injection phenomenon. Discontinue SYFOVRE in any patients who have these events.12

    • Severe vision loss defined as ≥6 lines loss from baseline.
    • Data on file from clinical trial and estimated real-world injections as of December 31, 2025. Injections are calculated based on vials distributed to eye care professional practices and estimates of patient numbers (extrapolated from licensed data and inventory levels from key accounts, representative of our market).12
    Learn more

  • What is the J Code for SYFOVRE® (pegcetacoplan injection)?

    The J Code for SYFOVRE is J2781.

    Learn more

  • How do you order SYFOVRE (pegcetacoplan injection)?

    SYFOVRE is available through 2 distribution channels: specialty distributors for buy and bill and specialty pharmacies. For more information on ordering SYFOVRE, click here.

    Learn more

  • Is financial assistance for SYFOVRE® (pegcetacoplan injection) available?

    Financial assistance is available for eligible patients with multiple types of insurance, limited coverage, or no insurance. For more information on financial assistance, click here.

    Learn more

  • Where can I find billing and coding information for SYFOVRE (pegcetacoplan injection)?

    To find tools and tips for information on billing, coding, and submitting claims for SYFOVRE, click here.

    Learn more
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
  • SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred.
WARNINGS AND PRECAUTIONS
  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Retinal Vasculitis and/or Retinal Vascular Occlusion
    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.
ADVERSE REACTIONS
  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.
INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information.